睿知中国医院研究地图
候选清单

正在招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07438106,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.

    入选标准第 2 条

    KRAS G12D mutation confirmed by tissue histology or peripheral blood testing.

    入选标准第 8 条

  3. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must not be lactating. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 180 days after the last dose of the study drug (whichever is later). A female is considered not of childbearing potential if postmenopausal for at least 1 year, or surgically sterilized (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

    入选标准第 25 条

    History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is not considered systemic therapy.

    排除标准第 3 条

    Major surgery (other than diagnostic biopsy) within 28 days prior to the first dose; minor traumatic surgery (biopsy, endoscopy, and drainage) within 7 days prior to the first dose; presence of non-healing wounds, untreated fractures.

    排除标准第 12 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

    入选标准第 9 条

  5. Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L.

    入选标准第 15 条

    White blood cell (WBC) count ≥3.0 × 10\^9/L.

    入选标准第 16 条

    Platelets ≥100 × 10\^9/L.

    入选标准第 17 条

    Hemoglobin >9 g/dL.

    入选标准第 18 条

    Total bilirubin ≤1.5 × upper limit of normal (ULN).

    入选标准第 20 条

    Prothrombin time and activated partial thromboplastin time ≤1.5 × ULN.

    入选标准第 21 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.

    入选标准第 22 条

    Serum creatinine ≤1.5 × ULN or creatinine clearance (calculated using Cockcroft-Gault formula) ≥50 mL/min.

    入选标准第 23 条

  6. At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    入选标准第 11 条

  7. Diagnosis of malignancies other than pancreatic cancer within 5 years prior to the first dose (excluding radically treated skin basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ).

    排除标准第 2 条

    History of drug abuse, chronic alcoholism, or infectious diseases such as AIDS (i.e., HIV-1/2 antibody positive).

    排除标准第 8 条

    Active hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07438106,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years and ≤75 years, regardless of gender.
  2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  3. Radiologically confirmed locally advanced disease, defined as:
  4. No distant metastasis.
  5. Pancreatic head/uncinate process tumors: Tumor contact with the superior mesenteric artery (SMA) >180°.
  6. Pancreatic body/tail tumors: Tumor contact with the SMA or celiac artery >180°; or contact with the celiac artery with aortic invasion; or tumor invasion of the jejunal branches of the SMA.
  7. Inability to safely reconstruct the portal vein-superior mesenteric vein due to tumor invasion, venous occlusion, or extensive involvement of the jejunal branches of the superior mesenteric vein.
  8. KRAS G12D mutation confirmed by tissue histology or peripheral blood testing.
  9. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  10. No prior antitumor therapy (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
  11. At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  12. If biliary obstruction is present, it must have been relieved prior to study entry, and the expected survival time is >3 months.
  13. Signed written informed consent obtained before performing any study-related procedures.
  14. Adequate organ function meeting the following criteria (without corrective treatment with blood components or growth factors within 14 days prior to the first dose), with test results completed within 7 days before initiation of study treatment:
  15. Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L.
  16. White blood cell (WBC) count ≥3.0 × 10\^9/L.
  17. Platelets ≥100 × 10\^9/L.
  18. Hemoglobin >9 g/dL.
  19. Albumin ≥3.0 g/dL.
  20. Total bilirubin ≤1.5 × upper limit of normal (ULN).
  21. Prothrombin time and activated partial thromboplastin time ≤1.5 × ULN.
  22. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
  23. Serum creatinine ≤1.5 × ULN or creatinine clearance (calculated using Cockcroft-Gault formula) ≥50 mL/min.
  24. Electrocardiogram: QTcF interval ≤450 msec for males and ≤470 msec for females.
  25. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must not be lactating. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 180 days after the last dose of the study drug (whichever is later). A female is considered not of childbearing potential if postmenopausal for at least 1 year, or surgically sterilized (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

排除标准:Exclusion Criteria:

  1. Presence of portal hypertension or cavernous transformation of the portal vein; tumor involvement of the gastrointestinal tract causing gastrointestinal bleeding; tumor leading to intra-abdominal fistula or abscess; tumor encasement of the celiac artery or superior mesenteric artery (SMA) with significant vascular wall involvement (moth-eaten appearance).
  2. Diagnosis of malignancies other than pancreatic cancer within 5 years prior to the first dose (excluding radically treated skin basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ).
  3. History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is not considered systemic therapy.
  4. Current use of systemic corticosteroid therapy (excluding topical, inhaled, nasal, or intra-articular corticosteroids) or any other form of immunosuppressive therapy within 7 days prior to the first study dose. Note: Use of physiologic doses of corticosteroids (≤10 mg/day prednisone or equivalent) is permitted.
  5. Known history of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
  6. History of allergy or hypersensitivity considered clinically significant by the investigator.
  7. Presence of clinically significant acute or chronic pancreatitis.
  8. History of drug abuse, chronic alcoholism, or infectious diseases such as AIDS (i.e., HIV-1/2 antibody positive).
  9. Uncontrolled active hepatitis B (defined as HBsAg positive with HBV-DNA level above the upper limit of normal at the local laboratory). Note: Participants with hepatitis B meeting the following criteria may be enrolled: 1) HBV viral load <10,000 copies/mL (2,000 IU/mL) prior to the first dose, and the participant should receive anti-HBV therapy throughout the study drug treatment period to prevent reactivation; 2) Participants who are anti-HBc positive, HBsAg negative, anti-HBs negative, and with negative HBV viral load do not require prophylactic anti-HV therapy but require close monitoring for reactivation.
  10. Active hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).
  11. Administration of a live attenuated vaccine within 28 days prior to the first study dose or anticipated need for a live attenuated vaccine during the study treatment period. Note: Administration of inactivated seasonal influenza vaccine within 28 days prior to the first dose is permitted; however, live attenuated intranasal influenza vaccines are not allowed.
  12. Major surgery (other than diagnostic biopsy) within 28 days prior to the first dose; minor traumatic surgery (biopsy, endoscopy, and drainage) within 7 days prior to the first dose; presence of non-healing wounds, untreated fractures.
  13. Presence of any severe or uncontrolled systemic disease, for example:
  14. Resting ECG showing significant uncontrolled abnormalities in rhythm, conduction, or morphology, such as complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmia, or atrial fibrillation.
  15. Unstable angina, congestive heart failure, chronic heart failure of New York Heart Association (NYHA) class ≥II.
  16. History of any arterial thrombotic, embolic, or ischemic event within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
  17. Poorly controlled blood pressure (systolic >150 mmHg or diastolic >100 mmHg).
  18. History of non-infectious interstitial lung disease requiring glucocorticoid therapy within 1 year prior to the first dose, or current clinically active interstitial lung disease.
  19. Active tuberculosis.
  20. Active or uncontrolled infection requiring systemic therapy.
  21. Clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction.
  22. Liver disease such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis.
  23. Low-density lipoprotein cholesterol (LDL-C) >3.4 mmol/L or severe hypertriglyceridemia (>5.7 mmol/L).
  24. Carotid ultrasound showing stenosis ≥50% or the presence of two or more high-risk characteristic plaques.
  25. History of severe infection within 28 days prior to the first dose, including but not limited to infection complications requiring hospitalization, bacteremia, or severe pneumonia; or active infection requiring therapeutic intravenous antibiotics within 2 weeks before starting study treatment. Participants receiving prophylactic antibiotics (e.g., for urinary tract infection prevention) may be enrolled.
  26. Any history, evidence of disease, treatment, or abnormal laboratory value that, in the investigator's judgment, could interfere with the trial results, prevent the participant from completing the study, indicate poor compliance, or pose potential risks making the participant unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07438106, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07438106,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07438106